Cell Signaling Technology

Product Pathways - Lineage Markers

SPARC Antibody #5420

Applications Reactivity Sensitivity MW (kDa) Source
W IP IF-IC H M Mk Endogenous 42 Rabbit

Applications Key:  W=Western Blotting  IP=Immunoprecipitation  IF-IC=Immunofluorescence (Immunocytochemistry)
Reactivity Key:  H=Human  M=Mouse  Mk=Monkey
Species cross-reactivity is determined by western blot. Species enclosed in parentheses are predicted to react based on 100% sequence homology.

Protocols

Specificity / Sensitivity

SPARC Antibody detects endogenous levels of total SPARC protein.

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Gly53 of human SPARC. Antibodies are purified by protein A and peptide affinity chromatography.

Western Blotting

Western Blotting

Western blot analysis of various cell extracts using SPARC Antibody. Jurkat are negative, as expected.

IF-IC

IF-IC

Confocal immunofluorescent analysis of NTERA-2 (left) and SW620 (right) cells using SPARC Antibody (green). Actin filaments were labeled with DY-554 phalloidin (red). Blue pseudocolor = DRAQ5® #4084 (fluorescent DNA dye).

Background

SPARC (secreted protein acidic and rich in cysteine), also known as osteonectin and BM40, is a secreted matricellular glycoprotein that belongs to a group of functionally related glycoproteins that includes tenascins C and X, thrombospondins 1 and 2, and osteopontin (1). Members in this class of glycoproteins are involved in tissue renewal, tissue remodeling, and embryonic development and work by exerting counter-adhesive and antiproliferative effects that lead to changes in cell shape, disruption of cell adhesion, and inhibition of the cell cycle (2). SPARC is expressed at high levels in bone tissue but is widely distributed in many other tissues and cell types (3), and is known to be associated with tissues undergoing morphogenesis, angiogenesis, mineralization, and other pathological responses to injury and tumorigenesis (4,5). SPARC has also been linked with obesity and diabetes (6).

  1. Fukunaga-Kalabis, M. et al. (2008) Cancer Microenviron 1, 93-102.
  2. Yan, Q. and Sage, E.H. (1999) J Histochem Cytochem 47, 1495-506.
  3. Maillard, C. et al. (1992) Bone 13, 257-64.
  4. Sage, E.H. (1997) Nat Med 3, 144-6.
  5. Bradshaw, A.D. and Sage, E.H. (2001) J Clin Invest 107, 1049-54.
  6. Kos, K. and Wilding, J.P. (2010) Nat Rev Endocrinol 6, 225-35.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products

For Research Use Only. Not For Use In Diagnostic Procedures.

Products